miRagen Therapeutics Named University of Colorado Technology Transfer Office Bioscience Company of the Year

BOULDER, Colo.--(BUSINESS WIRE)-- miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that it is the recipient of the University of Colorado (CU) Technology Transfer Office Bioscience Company of the Year award. The award will be conferred this evening at the CU Technology Transfer Annual Awards Banquet in Denver.

miRagen Therapeutics and CU signed research and licensing agreements in October 2010 launching their collaboration on microRNA therapeutics discovery and development. The collaboration is focused on microRNA profiling of a human heart failure study conducted at CU.

“We are honored to be recognized by the University of Colorado with this award, and pleased to be working with them on the Beta Blocker Effects on Remodeling and Gene Expression (BORG) study,” said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics, Inc. “Our collaboration with CU provides us with access to unique data in patients with heart failure, which further advances our mission of developing groundbreaking microRNA-based therapeutics to treat patients with cardiovascular and muscle disease.”

“The University is very happy to honor miRagen for its accomplishments both in and outside of its relationship with the University this past year,” said David Allen, CU Associate Vice President for Technology Transfer. “We have had a very productive and successful relationship with miRagen since its inception, and we look forward to that relationship continuing and growing even more productive in the future.”

About microRNAs: microRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are associated with many disease processes. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets for controlling many biologic and disease processes.

About miRagen Therapeutics: miRagen Therapeutics, Inc., was founded in 2007 to develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. Only recently discovered, microRNAs are short, single-stranded RNA molecules encoded in the genome that regulate gene expression and play a vital role in influencing cardiovascular and muscle disease. Cardiovascular disease is the leading cause of death globally and represents an enormous burden on global healthcare systems. Principally funded through venture capital investments, miRagen combines world recognized leadership in cardiovascular medicine with unprecedented in-house expertise in microRNA biology and chemistry. For more information, please visit www.miragentherapeutics.com.


Scout Investor Relations (for miRagen Therapeutics)
Anna Sussman, 303-907-5358
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Pharmaceutical